LivaNova Q2 Earnings Call Highlights
LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.
How this was made
The 30-second read
Why it matters
The most tradable elements are the explicit upward revisions to 2026 revenue-growth and adjusted diluted EPS, alongside the cash-flow tradeoff (higher capex, lower adjusted free-cash-flow guidance). Supply constraints easing via a long-term Thermo Fisher agreement and Medicare/CMS reimbursement support are key demand and margin narratives.
Market read
Traders can reprice near-term expectations using the raised 2026 growth and EPS guidance, while monitoring the capex and FCF guidance downgrade for cash-flow sensitivity.
What to watch
The article notes higher IT and R&D spend plus increased capex and lowered FCF guidance, which could matter more to valuation than top-line growth.
Background
This is a highlights recap of LivaNova’s Q2 earnings call, including operational updates, reimbursement commentary, pipeline milestones, and full-year guidance changes.
Ticker impact
LivaNova raised 2026 cardiopulmonary and epilepsy revenue-growth forecasts and EPS guidance after citing supply improvements and stronger realized pricing.
Likely positive bias for the stock on guidance strength, with some profit-taking risk if investors focus on capex and reduced FCF outlook.
The article contains multiple explicit forecast changes (revenue growth, EPS, capex, and FCF) plus operational drivers (oxygenator output, Medicare/CMS reimbursement, pricing).
Market effects
Supports sentiment for medical device makers tied to reimbursement and procedure volumes, especially cardiopulmonary oxygenators and neuromodulation.
CMS/Medicare reimbursement commentary is US-specific and may influence expectations for US procedure-driven medtech demand.
Oxygenator supply agreement and production-line ramp are medium-term drivers that can affect global hospital procurement planning.
Counterpoint
Raised revenue and EPS guidance may be offset by execution risk around the 2026 production line ramp and the 2027-2028 pipeline timelines.
Key entities
- companyLivaNova
NASDAQ-listed medical technology company providing cardiopulmonary oxygenators and neuromodulation therapies.
- counterpartyThermo Fisher Scientific
Entered into a long-term agreement with LivaNova to secure a critical oxygenator component.
- regulatorCMS
US Centers for Medicare and Medicaid Services, referenced for preliminary reimbursement classification and proposed end-of-service changes.
